G protein-coupled receptor 65Genealiases: TDAG8 · hTDAG8
Q-omics provides the consensus-scored GPR65 profile across patient tissues and cancer cell-line models. GPR65 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GPR65 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GPR65 RNA expression shows 22,400 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where GPR65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR65 survival associations across molecular data types. GPR65 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR65 RNA expression–survival associations across cancer types. High GPR65 expression shows unfavorable associations in LGG and UVM, but favorable associations in SKCM, HNSC, CESC and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GPR65 RNA expression.
This table summarizes GPR65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GPR65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR65 shows lower tumor expression in LUAD, LUSC and BLCA and higher tumor expression in KIRC, KIRP and BRCA. The KIRC box plot shows higher GPR65 RNA expression in tumor versus normal tissue (log2 FC = +1.694, t-test p < 0.001).
This table shows molecular features associated with GPR65 in patient tissues and cancer cell lines. In patient samples, GPR65 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
